Search Results - (Author, Cooperation:J. Bousquet)
-
1Latest Papers from Table of Contents or Articles in PressB. Nystedt ; N. R. Street ; A. Wetterbom ; A. Zuccolo ; Y. C. Lin ; D. G. Scofield ; F. Vezzi ; N. Delhomme ; S. Giacomello ; A. Alexeyenko ; R. Vicedomini ; K. Sahlin ; E. Sherwood ; M. Elfstrand ; L. Gramzow ; K. Holmberg ; J. Hallman ; O. Keech ; L. Klasson ; M. Koriabine ; M. Kucukoglu ; M. Kaller ; J. Luthman ; F. Lysholm ; T. Niittyla ; A. Olson ; N. Rilakovic ; C. Ritland ; J. A. Rossello ; J. Sena ; T. Svensson ; C. Talavera-Lopez ; G. Theissen ; H. Tuominen ; K. Vanneste ; Z. Q. Wu ; B. Zhang ; P. Zerbe ; L. Arvestad ; R. Bhalerao ; J. Bohlmann ; J. Bousquet ; R. Garcia Gil ; T. R. Hvidsten ; P. de Jong ; J. MacKay ; M. Morgante ; K. Ritland ; B. Sundberg ; S. L. Thompson ; Y. Van de Peer ; B. Andersson ; O. Nilsson ; P. K. Ingvarsson ; J. Lundeberg ; S. Jansson
Nature Publishing Group (NPG)
Published 2013Staff ViewPublication Date: 2013-05-24Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Conserved Sequence/genetics ; DNA Transposable Elements/genetics ; *Evolution, Molecular ; Gene Silencing ; Genes, Plant/genetics ; Genome, Plant/*genetics ; Genomics ; Internet ; Introns/genetics ; Phenotype ; Picea/*genetics ; RNA, Untranslated/genetics ; Sequence Analysis, DNA ; Terminal Repeat Sequences/genetics ; Transcription, Genetic/geneticsPublished by: -
2Articles: DFG German National LicensesStaff View
ISSN: 1471-0528Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Summary. The serum of pregnant women contains a non-specific immuno-suppressive factor able to block an in vitro cellular cytotoxicity reaction. This activity increases during the first trimester and persists for 3 months after delivery. The factor is active in dilution. Ten women who had recurrent abortions were typed for HLA antigens and were found to share several antigens with their husband. In all these women, the‘blocking factor’was absent from their serum. The absence of the‘blocking factor’could be used as a clinical test to predict spontaneous abortion.Type of Medium: Electronic ResourceURL: -
3Articles: DFG German National LicensesLebel, B. ; Arnoux, B. ; Chanez, P. ; Bougeard, Y.-H. ; Daures, J. P. ; Bousquet, J. ; Campbell, A. M.
Oxford, UK : Blackwell Publishing Ltd
Published 1996Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Histamine is one of a range of mediators which play an important role in asthma, and the “releasability” of basophils has been shown to be upregulated in this disease. In vitro, β2-agonists and to a lesser extent corticosteroids have been shown to reduce histamine release. The ex vivo effects of salmeterol and inhaled corticosteroids on histamine release were studied in 78 asthmatic patients with variable disease severity and 20 control subjects. Spontaneous and anti-IgE-induced histamine release was measured in all subjects. Fifteen patients were not receiving any form of treatment, 42 were treated with inhaled corticosteroids, and 21 received inhaled corticosteroids and salmeterol. Seven patients treated with inhaled corticosteroids and seven patients treated with inhaled corticosteroids and salmeterol were tested twice to assess the effect of salmeterol on histamine release. Nine patients treated with inhaled corticosteroids were tested before and after 1 month of salmeterol treatment to determine the possible inhibition by salmeterol. Patients who were treated with inhaled corticosteroids and salmeterol showed significantly lower levels of spontaneous histamine release (median: 2.5%) than untreated (5.2%) and inhaled corticosteroids-treated asthmatics (3.4%). No tachyphylaxis to salmeterol was observed when patients were tested twice at a 3-month interval. This study suggests that salmeterol may have an additive anti-inflammatory effect with inhaled corticosteroids, although this hypothesis must be tested by further studies involving cells obtained by bronchoalveolar lavage and studies with bronchial biopsies.Type of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesFabre, J. M. ; Marty-Ane, C. ; Alauzen, M. ; Souques, F. ; Bousquet, J. ; Campbell, A. M.
Oxford, UK : Blackwell Publishing Ltd
Published 1995Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: H1-blockers may have antiallergic properties which cause the blocking of eicosanoid release, and the effect of these drugs may differ according to the phenotype of mast cells. This study examined the ability of terfenadine and cetirizine to inhibit the release of arachidonic acid-derived mediators from human lung and colon cells. Dispersed cells were challenged with anti-IgE in the presence or absence of 10 μM of terfenadine or cetirizine, and the release of prostaglandin (PG)D2 and leukotriene (LT)C4/D4 was assessed by enzyme immunoassay (EIA). Terfenadine caused significant inhibition of both PGD2 and LTC4/D4 (49 ±9 and 29 ± 19%, respectively) from human lung cells but had a less marked effect on PGD2 release from human colon cells (21 ± 9% for PGD2 and 18 ± 9% for LTC4/D4). In contrast, although cetirizine caused significant inhibition of both mediators measured in lung cells (38 ± 16% for PGD2 and 34 ± 19% for LTC4), it did not cause any significant inhibition of either mediator from human colon cells. These findings suggest that H1antagonists may have additional properties, and the differential effects of cetirizine on lung and colon tissue may indicate differences in mast cell phenotype.Type of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesChanez, P. ; Vignola, M. ; Stenger, R. ; Vic, P. ; Michel, F.B. ; Bousquet, J.
Oxford, UK : Blackwell Publishing Ltd
Published 1995Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Platelet-derived growth factor (PDGF) controls cellular growth, migration, and differentiation. It is secreted by various cell types, including macrophages, and participates in tissue repair and epithelial regeneration. PDGF may therefore be involved in airway remodeling in asthma. This study compared the immunoreactivity of PDGF and its receptors (Rα and Rβ) in bronchial biopsies and the levels of PDGF in bronchoalveolar lavage (BAL) fluid of asthmatics and control subjects. Bronchial biopsies were done in a subsegmental bronchus of 11 asthmatics and 11 control subjects by flexible bronchoscope. PDGF AA and BB, and PDGF receptors Rα and Rβ were studied with monoclonal antibodies and revealed by immunoperoxidase staining. The percentage of subjects presenting positive staining with PDGFs and its receptors was studied in the epithelium and submucosa. PDGF AA, AB, and BB were measured in BAL fluid of 18 asthmatics and 10 controls by specific ELISA. In biopsies, there was no significant difference between asthmatics and controls for PDGF AA, BB, PDGF-Rα and R4bT (Fisher's exact test and Bonferroni's correction). Moreover, the levels of PDGF, AA, AB, and BB were similar in asthmatics and controls. This study does not support a role for PDGF in the repair processes of asthma.Type of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesBousquet, J. ; Chanal, I. ; Murrieta, M. ; Stalla-Bourdillon, A.
Oxford, UK : Blackwell Publishing Ltd
Published 1996Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Mizolastine is a new, nonsedating antihistamine providing satisfactory symptom relief in allergic rhinitis and urticaria. The purpose of this study was to use the wheal and flare skin reactions model to assess the maintenance of the pharmacodynamic effect of mizolastine, administered for 2 months. This double-blind, parallel-group study involved 60 atopic patients randomly allocated, after a 1-week placebo run-in, to once-daily 10 mg mizolastine (n= 29) or placebo (n= 31) groups. Treatment continued for 8 weeks. Prick tests were performed in duplicate with histamine chlorhydrate (10mg/ml), codeine phosphate (9%), and five increasing concentrations (1–500 reactivity index/ml) of standardized allergen extracts (grass pollen or mites) at days 0, 7, 28, 42, and 56. After 7 days of treatment, inhibition of histamine-induced wheal was -76% and + 20%, respectively, with mizolastine and placebo (P= 0.0001), in comparison with baseline; inhibition of flare was - 86% and + 50%, respectively, with mizolastine and placebo (P = 0.0001). Suppression was maintained to a similar extent throughout the study. Results were consistent between histamine-, codeine-, and allergen-induced tests. Safety was satisfactory in both groups. This study confirms mizolastine as a potent antihistamine which does not induce subsensitivity when taken for 8 weeks, and which can be safely recommended in allergic conditions.Type of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesStaff View
ISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesBousquet, J. ; Chanez, P. ; Lacoste, J. Y. ; White, R. ; Vic, P. ; Godard, P. ; Michel, F. B.
Oxford, UK : Blackwell Publishing Ltd
Published 1992Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesBousquet, J. ; Héadon, B. ; Hejjaoui, A. ; Chanal, L ; Michel, F.-B.
Oxford, UK : Blackwell Publishing Ltd
Published 1988Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Busereline acetate is an LH-RH agonist that was found to induce local reactions at the injection site or generalized minor skin reactions in some patients. Since these reactions may represent the first reaction of systemic anaphylaxis, we tested the non-specific histamine releasing activity of this drug by intradermal skin tests. It was found that all subjects tested had a positive wheal and flare reaction, the flare being significantly decreased by terfenadine. Benzyl alcohol, the preservative used in commercial preparation of busereline acetate, did not elicit a positive wheal and flare reaction in two patients who had experienced a clinically noticeable reaction. It is concluded that busereline is likely to be a non-specific histamine releasing compound.Type of Medium: Electronic ResourceURL: -
10Articles: DFG German National LicensesBousquet, J. ; Cabrera, P. ; Berkman, N. ; Buhl, R. ; Holgate, S. ; Wenzel, S. ; Fox, H. ; Hedgecock, S. ; Blogg, M. ; Cioppa, G. Della
Oxford, UK : Munksgaard International Publishers
Published 2005Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background: Patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma management guidelines have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.Methods: Here, we pooled data from seven studies to determine the effect of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, on asthma exacerbations in patients with severe persistent asthma. Omalizumab was added to current asthma therapy and compared with placebo (in five double-blind studies) or with current asthma therapy alone (in two open-label studies). The studies included 4308 patients (2511 treated with omalizumab), 93% of whom had severe persistent asthma according to the Global Initiative for Asthma (GINA) 2002 classification. Using the Poisson regression model, results were calculated as the ratio of treatment effect (omalizumab : control) on the standardized exacerbation rate per year.Results: Omalizumab significantly reduced the rate of asthma exacerbations by 38% (P 〈 0.0001 vs control) and the rate of total emergency visits by 47% (P 〈 0.0001 vs control). Analysis of demographic subgroups showed that the efficacy of omalizumab on asthma exacerbations was unaffected by patient age, gender, baseline serum IgE (split by median) or by 2- or 4-weekly dosing schedule, although benefit in absolute terms appeared to be greatest in patients with more severe asthma, defined by a lower value of percentage predicted forced expiratory volume in 1 s (FEV1) at baseline.Conclusions: These results suggest that omalizumab may fulfil an important need in patients with severe persistent asthma, many of whom are not adequately controlled on current therapy.Type of Medium: Electronic ResourceURL: -
11Articles: DFG German National LicensesMatricardi, P. M. ; Bjorksten, B. ; Bonini, S. ; Bousquet, J. ; Djukanovic, R. ; Dreborg, S. ; Gereda, J. ; Malling, H.-J. ; Popov, T. ; Raz, E. ; Renz, H.
Oxford, UK : Munksgaard International Publishers
Published 2003Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
12Articles: DFG German National LicensesVignola, A. M. ; Scichilone, N. ; Bousquet, J. ; Bonsignore, G. ; Bellia, V.
Oxford, UK : Munksgaard International Publishers
Published 2003Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
13Articles: DFG German National LicensesStaff View
ISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
14Articles: DFG German National LicensesAnnesi-Maesano, I. ; Didier, A. ; Klossek, M. ; Chanal, I. ; Moreau, D. ; Bousquet, J.
Oxford, UK : Blackwell Science, Ltd
Published 2002Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background: No validated assessment of allergic rhinitis (AR) is presently available that can be used in population studies in the absence of medical diagnosis and of objective measurements of allergy. To compensate for this lack, a quantitative Score For Allergic Rhinitis (SFAR) ranging between 0 and 16 has been developed by experts. Methods: The SFAR, encompassing eight features of AR, was validated in three different ways: 1) among 269 outpatients taking the specialist's diagnosis of AR and skin prick tests (SPT) positivity as a gold standard (diagnosis validation); 2) using psychometric methods (internal validation); and 3) in a random population-based sample of 3001 individuals by telephone interview (population acceptability). Results: A SFAR value ≥ 7 allowed satisfactory discrimination between the outpatients with AR from those without (sensitivity = 74% [95% confidence interval CI: 0.69,0.79], specificity = 83% [0.79, 0.87], positive predictive value = 84% [0.80, 0.88], negative predictive value = 74% [0.69, 0.79] and Youden's index = 0.57, respectively). Internal consistency of the score was also high (among others, Cronbach's alpha coefficient = 0.79). On average, it took only 3 min for the individuals interviewed on the phone to complete the questionnaire, the questions of which were well understood. Among these subjects, the prevalence of AR was 21% [95% CI: 19.5%, 22.5%], which is comparable to other determinations in France. Conclusions: The newly a priori proposed Score For Allergic Rhinitis (SFAR) is easy to use and can be useful to estimate prevalence and to study causation of AR in population settings.Type of Medium: Electronic ResourceURL: -
15Articles: DFG German National LicensesPiette, V. ; Bourret, E. ; Bousquet, J. ; Demoly, P.
Oxford, UK : Munksgaard International Publishers
Published 2002Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background: Improperly performed skin prick tests (SPT) can lead to wrong allergy diagnosis and incorrect treatment. To overcome false-positive results it is recommended to change the puncture device between each test, although very few studies have examined the real drawbacks (false-positives) and advantages (time and cost savings) of using only one device.Methods: Two groups of 20 patients with rhinitis or asthma, sensitized to either house-dust mites or grass pollens, had successive serial SPT to 9% codeine phosphate and the relevant allergen using the same needle or lancet, wiped between each test.Results: With both the needle and the lancet, there were 12.5–67.5% false-positive results using the house-dust mite or grass pollen allergen extracts, respectively. There were no false-positive results with the 9% codeine phosphate.Conclusions: Our study shows that this technique is not reliable as it provoked an unacceptable number of false-positive results.Type of Medium: Electronic ResourceURL: -
16Articles: DFG German National LicensesStaff View
ISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
17Articles: DFG German National LicensesLebel, B. ; Messaad, D. ; Kvedariene, V. ; Rongier, M. ; Bousquet, J. ; Demoly, P.
Copenhagen : Munksgaard International Publishers
Published 2001Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background: The diagnosis of allergic reactions to drugs is difficult. Most skin tests are not standardized, and in vitro tests are needed to avoid provocation tests. Cross-linking of IgE on basophils is known to cause the release of both cysteinyl leukotriene (Cys-LT) and histamine. We aimed to evaluate the diagnostic utility (sensitivity, specificity, and efficiency) of measurement of sulfidoleukotrienes in drug allergy. Methods: We performed a prospective study in 55 patients with proven immediate adverse reactions to drugs (30 to β-lactams, six to acetaminophen, and 19 to aspirin) and 64 drug-exposed nonallergic controls. Positive diagnosis was established by history, skin tests, and, if needed, oral provocation tests. Cys-LT release was determined after drug-allergen stimulation by the cellular antigen stimulation test (CAST®) technique. Histamine release was also assessed on the same samples by enzyme immunoassay. Spontaneous and anti-FcεRIα-induced mediator release was also studied in all subjects. Sensitivity, specificity, and efficiency were calculated. Results: Net Cys-LT release was over the maximal threshold given by the manufacturer in 19/55 patients and in 9/64 controls. Net histamine release was over 5% of total histamine content in 28/55 patients and 34/64 controls. The efficiency of both tests was low. Conclusions: Thus, in most cases, the in vitro Cys-LT test has little or no diagnostic utility and is not superior to histamine release.Type of Medium: Electronic ResourceURL: -
18Articles: DFG German National LicensesRaison-Peyron, N. ; Messaad, D. ; Bousquet, J. ; Demoly, P.
Copenhagen : Munksgaard International Publishers
Published 2001Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineType of Medium: Electronic ResourceURL: -
19Articles: DFG German National LicensesSaporta, M. ; Kamei, S. ; Persi, L. ; Bousquet, J. ; Arnoux, B.
Copenhagen : Munksgaard International Publishers
Published 2001Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background: Basotest® is a new basophil-activation test based upon the expression of CD63 (gp53) in the presence of allergens. It is an effective diagnostic test for pollen-allergic patients. However, it is not known whether Basotest results differ during the pollen season. Methods: We examined the activation of basophils by Basotest in 13 patients sensitized only to grass pollen, before and during the pollen season, in order to assess whether Basotest could be used as a diagnostic test during the pollen season. Dose-response curves with 10-fold increasing concentrations of timothy grass pollen (10−4 to 100 AU) were carried out. Results: Basophils were not activated spontaneously during the pollen season since the CD63 expression was below detectable levels before in vitro cell activation. A decreased percentage of activated basophils at the peak of activation was found in comparing the pre- and in-season tests, but all patients had a positive test. When basophil activation was at its peak, the allergen concentration was similar during the two periods. Moreover, the median area under the curve was significantly (P〈0.02) reduced during the season as compared to before the season. Conclusions: Basotest can therefore be used as a diagnostic test during the pollen season, but the allergen exposure needs to be characterized if quantitative studies are performed.Type of Medium: Electronic ResourceURL: -
20Articles: DFG German National LicensesBousquet, J. ; Czarlewski, W. ; Cougnard, J. ; Danzig, M. ; Micher, F.-B.
Oxford, UK : Blackwell Publishing Ltd
Published 1998Staff ViewISSN: 1398-9995Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: New-generation H-blockers may possess antiallergic properties, and their effect may differ, depending on the target organ. A double-blind, placebo-controlled, parallel-group study was carried out during the pollen season to compare the clinical effect on nasal and conjunctival symptoms of astemizole (10 mg o.d.) and loratadine (10 mg o.d.) with their effect on skin-test reactivity to allergen and histamine. Thirty-eight patients (12–56 years of age) were studied. Nasal and ocular symptoms were recorded daily from days 4 to 7. Skin prick tests with serial concentrations of allergens and one concentration of histamine were carried out before and at the end of the 7-day treatment period. Parallel-line bioassay, analysis of variance, and covariance were used to analyze skin test data. Loratadine and astemizole significantly decreased symptoms from baseline (P〈0.004 and P〈0.006), Skin-test reactivity to allergen and histamine was more profoundly decreased by astemizole than loratadine. The histamine covariant was more important in the allergen effect of astemizole than in that of loratadine. Two Hblockers having the same clinical effect on nasal and ocular symptoms during the pollen season have totally different effects on skin-test reactivity. Skin-test reactivity to allergen or histamine is not predictive of the clinical efficacy of H1-blockers during seasonal allergic rhinitis.Type of Medium: Electronic ResourceURL: